Jonathan Alicea | Authors


Study Shows AKT1 E17K a Targetable Mutation Through AKT Inhibition Across Various Cancer Types

November 07, 2017

Amultihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the Journal of Clinical Oncology.

Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain

September 01, 2017

Corey Langer, MD, provides details on the goals and implications of the KEYNOTE-021 trial. Moreover, he discusses the current arena in NSCLC treatment and the obstacles that remain in treating patients without driver mutations effectively.